Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

LifeStance Health (LFST) Shares Outstanding (Weighted Average) (2020 - 2024)

Historic Shares Outstanding (Weighted Average) for LifeStance Health (LFST) over the last 5 years, with Q4 2024 value amounting to $379.1 million.

  • LifeStance Health's Shares Outstanding (Weighted Average) rose 318.13% to $379.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $379.1 million, marking a year-over-year increase of 318.13%. This contributed to the annual value of $379.1 million for FY2024, which is 318.13% up from last year.
  • Per LifeStance Health's latest filing, its Shares Outstanding (Weighted Average) stood at $379.1 million for Q4 2024, which was up 318.13% from $380.4 million recorded in Q3 2024.
  • LifeStance Health's 5-year Shares Outstanding (Weighted Average) high stood at $380.4 million for Q3 2024, and its period low was $302657.0 during Q3 2020.
  • In the last 5 years, LifeStance Health's Shares Outstanding (Weighted Average) had a median value of $326.3 million in 2020 and averaged $201.9 million.
  • In the last 5 years, LifeStance Health's Shares Outstanding (Weighted Average) tumbled by 9989.45% in 2021 and then skyrocketed by 10837421.4% in 2022.
  • Quarter analysis of 5 years shows LifeStance Health's Shares Outstanding (Weighted Average) stood at $302657.0 in 2020, then grew by 8.22% to $327523.0 in 2021, then skyrocketed by 108374.21% to $355.3 million in 2022, then grew by 3.43% to $367.5 million in 2023, then increased by 3.18% to $379.1 million in 2024.
  • Its Shares Outstanding (Weighted Average) was $379.1 million in Q4 2024, compared to $380.4 million in Q3 2024 and $379.4 million in Q2 2024.